We develop impactful, integrated commercial and clinical strategy across the lifecycle of products – from pre-launch excellence response to market changes and end-of-lifecycle products.
Working in cross-functional, commercial and medical teams, we work with you to develop strategy to challenge the dynamic and competitive market you operate in.
| 29th September 2015
With pharma in the midst of a patent cliff, portfolios of treatments are becoming more and more common, and the need for a clear co-positioning strategy has never been greater.
Head of Brand Strategy Jenna Earl talks us through the three most important things to understand about portfolio positioning in pharma.
| 23rd September 2015
Recently, Blue Latitude Health worked with a global pharmaceutical brand to develop a strategy for dealing with the introduction of biosimilars to the market. Their product, a treatment in the gastroenterology therapy area, had recently come off patent and a biosimilar was about to launch. Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars.
| 22nd July 2015
Recently, we’ve worked across multiple brands in oncology on launch and pre-launch strategy, which raises a unique set of challenges in a competitive and highly regulated market. Matt Bolton, Head of Commercial, takes us through the three key points to keep in mind when developing a pharmaceutical pre-launch positioning strategy.
| 12th March 2015
The modern pharmaceutical market can be saturated with competing products, from bio-similars, to same in-class, to alternative MoA treatments. Standing out from the crowd can be tough; innovative and patient serving methods of differentiation are hard to come by.
Consultant Mark Assenti talks through the use of biomarkers in pharma marketing and where it's headed in 2015.